ARYA Atherosclerosis Journal

Serum interleukin-18 and its relationship with subclinical atherosclerosis in systemic lupus erythematosus

Document Type : Short Communication

Authors

Zahra Rezaieyazdi 1
Mina AkbariRad 2
Nayyereh Saadati 1
Masoumeh Salari 1
Reza Orang 1
Sima Sedighi 3
Habibollah Esmaily 4
Mahmoud Reza Azarpazhooh 4
Abdollah Firoozi 5
Ensieh Akbarpour 6

1 Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Assistant Professor, Department of Internal Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

4 Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

5 Pharmacist, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

6 Department of Epidemiology and Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran

https://doi.org/10.22122/arya.v17i0.2126
Abstract
BACKGROUND: Interleukin-18 (IL-18) is a pro-inflammatory and pro-atherogenic factor, and its blood level has shown a direct correlation with atherosclerosis. We aimed to evaluate the serum IL-18 level in patients with systemic lupus erythematosus (SLE) and its relationship with the intima-media thickness (IMT) of the carotid artery in these patients, as an indicator of atherosclerosis.METHODS: In this cross-sectional study, 60 patients as the patient group and 30 healthy volunteers as the control group [matched sex, age, and body mass index (BMI)] were selected, and their disease status and general data were gathered using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) form. A blood sample was also obtained from all participants to determine the serum level of IL-18 and other metrics, including high-sensitivity C-reactive protein (hs-CRP), cholesterol, triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), anti-double stranded deoxyribonucleic acid (anti-dsDNA), complement 3 (C3), and C4. The IMT of the carotid artery was calculated in both groups. We also evaluated the clinical cardiovascular manifestations.RESULTS: The serum IL-18 levels in patients were significantly higher than in the control group (P ˂ 0.005). It had no significant correlation with disease activity (P = 0.10). The patients with SLE with high IL-18 serum levels (> 280 pg/ml) had higher SLEDAI-2K (P = 0.02) than the patients with a low level (< 280), where 280 was the median of the IL-18 levels. The serum IL-18 level had no significant correlation with the carotid artery IMT.CONCLUSION: A high level of IL-18 reflects the disease activity, but it was not significantly correlated with subclinical atherosclerosis, denoted by the carotid artery IMT.

Keywords

Systemic Lupus Erythematosus
Interleukin18
Atherosclerosis
  1. Migliorini P, Anzilotti C, Pratesi F, Quattroni P, Bargagna M, Dinarello CA, et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Netw 2010; 21(4): 264-71.
  2. Park JK, Kim JY, Moon JY, Ahn EY, Lee EY, Lee EB, et al. Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: A potential role in atherosclerosis. Arthritis Res Ther 2016; 18(1): 306.
  3. Nicolaou O, Kousios A, Hadjisavvas A, Lauwerys B, Sokratous K, Kyriacou K. Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: A systematic review. J Cell Mol Med 2017; 21(5): 993-1012.
  4. Jafari-Nakhjavani MR, Abedi-Azar S, Nejati B. Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus. J Nephropathol 2016; 5(1): 28-33.
  5. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006; 188(2): 450-4.
  6. Italiani P, Manca ML, Angelotti F, Melillo D, Pratesi F, Puxeddu I, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther 2018; 20(1): 27.
  7. Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, et al. Harrison's principles of internal medicine. 17th ed. New York, NY: McGraw Hill; 2008.
  8. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35(6): 630-40.
  9. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A, et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: Results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2007; 27(9): 2043-9.
  10. Tso TK, Huang WN, Huang HY, Chang CK. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45(9): 1148-53.
  11. Bhat OM, Kumar PU, Giridharan NV, Kaul D, Kumar MJ, Dhawan V. Interleukin-18-induced atherosclerosis involves CD36 and NF-kappaB crosstalk in Apo E-/- mice. J Cardiol 2015; 66(1): 28-35.
  12. Duan Z, Zhang Y, Zeng Z, Pan F. Comment on "Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus". J Immunol 2012; 189(2): 499-500.
  13. Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. Analysis of Serum Interleukin (IL)-1beta and IL-18 in Systemic Lupus Erythematosus. Front Immunol 2018; 9: 1250.
  14. Umare V, Pradhan V, Nath S, Rajadhyaksha A, Ghosh K, Nadkarni AH. Impact of functional
  15. IL-18 polymorphisms on genetic predisposition and diverse clinical manifestations of the disease in Indian SLE patients. Lupus 2019; 28(4): 545-54.
  16. Xiang M, Feng Y, Wang Y, Wang J, Zhang Z, Liang J, et al. Correlation between circulating interleukin-18 level and systemic lupus erythematosus: A meta-analysis. Sci Rep 2021; 11(1): 4707.
  17. Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE, Woodward M, et al. Interleukin 18 and coronary heart disease: Prospective study and systematic review. Atherosclerosis 2011; 217(1): 227-33.
  18. Teixeira V, Tam LS. Novel insights in systemic lupus erythematosus and atherosclerosis. Front Med (Lausanne) 2017; 4: 262.
  19. Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y, et al. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 2005; 25(7): 1458-62.
  20. Correale M, Brunetti ND, Di BM. The pro-inflammatory role of cytokines in the mechanism of atherosclerosis. G Ital Cardiol (Rome) 2006; 7(9): 594-603. [In Italian].
  21. Bhatt SP, Handa R, Gulati GS, Sharma S, Pandey RM, Aggarwal P, et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol 2006; 35(2): 128-32.
  22. Chen S, Jiang F, Ren J, Liu J, Meng W. Association of IL-18 polymorphisms with rheumatoid arthritis and systemic lupus erythematosus in Asian populations: A meta-analysis. BMC Med Genet 2012; 13: 107.
ARYA Atherosclerosis Journal
Volume 17, Issue 1
January and February 2021
Pages 1-6

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us